HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step  by Federico, Maurizio
Virology 417 (2011) 37–49
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roHIV-protease inhibitors block the replication of both vesicular stomatitis and
inﬂuenza viruses at an early post-entry replication step
Maurizio Federico ⁎
National AIDS Center, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161, Rome, Italy⁎ Corresponding author. Fax: +39 06 49903002.
E-mail address: maurizio.federico@iss.it.
0042-6822/$ – see front matter © 2011 Elsevier Inc. Al
doi:10.1016/j.virol.2011.05.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 February 2011
Accepted 9 May 2011
Available online 28 May 2011
Keywords:
HIV-protease inhibitor
Vesicular stomatitis virus
Inﬂuenza virus
Virus endocytosis
VSV envelope glycoproteinThe inhibitors of HIV-1 protease (PIs) have been designed to block the activity of the viral aspartyl-protease.
However, it is now accepted that this family of inhibitors can also affect the activity of cell proteases. Since the
replication of many virus species requires the activity of host cell proteases, investigating the effects of PIs on
the life cycle of viruses other than HIV would be of interest. Here, the potent inhibition induced by saquinavir
and nelﬁnavir on the replication of both vesicular stomatitis and inﬂuenza viruses is described. These are
unrelated enveloped RNA viruses infecting target cells upon endocytosis and intracellular fusion. The PI-
induced inhibition was apparently a consequence of a block at the level of the fusion between viral envelope
and endosomal membranes. These ﬁndings would open the way towards the therapeutic use of PIs against
enveloped RNA viruses other than HIV.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
HIV protease inhibitors (PIs) are a family of small molecules
speciﬁcally designed for blocking the activity of the HIV aspartyl-
protease (for a review, see Flexner, 1998). The PI treatment leads to
the block of HIV maturation with consequent release of non-
infectious viral particles (Kaplan et al., 1993). PIs exert their
inhibitory effect by disabling the enzyme before it can cleave the
Gag–Pol polyprotein into its essential products. PIs, together with
anti-HIV compounds targeting alternative steps of the virus life
cycle, are part of the most advanced anti-HIV therapies allowing
millions of infected people to co-exist with the virus experiencing a
good quality of life. However, it is now clear that PIs can also
directly or indirectly inhibit the activity of many cell proteases. In
particular, PIs can inhibit the activity of both 20S (André et al.,
1998) and 26S (Pajonk et al., 2002) proteasome subunits, as well as
that of caspases (Badley, 2005), with alterations in the susceptibil-
ity to apoptosis stimuli. Both expression and release of matrix-
metalloproteinases (MMPs) can be also targeted by PIs (Bourlier
et al., 2005; De Barros et al., 2007) with consequences in the extra-
cellular matrix modeling and, more in general, in the cell–cell
communication. In addition, PIs have been found inhibiting cell
signaling pathway involving both NF-κB (Dewan et al., 2009) and
AKT (Kumar et al., 2009; Srirangam et al., 2006). From a clinical
point of view, the PI treatment may induce beneﬁcial effects otherthan those against HIV, as in the case of Kaposi sarcoma regression
(Sgadari et al., 2002), but can also have detrimental consequences,
as for the dyslipidemia occurring in PI-treated HIV patients
(Calza et al., 2004).
To enter target cells, enveloped RNA viruses fuse their envelope
either at the cell surface in a pH-independent way, or upon
internalization in intracellular vesicles through a pH-dependent
mechanism (Steven and Spear, 2006). In this latter case, low pH is
required to induce the fusion between viral envelope and
endosomal membranes, a phenomenon leading to the release of
virion contents into cytoplasm. Although the viral fusion process is
guided by the presence of viral envelope proteins, the contribution
of cell proteins is critical. Using RNA interference as a tool for gene
expression inhibition, it was demonstrated that several cell
proteins are involved in the mechanism of entry of many viruses
including HIV-1 (Brass et al., 2008; Nguyen et al., 2006), inﬂuenza
(Hao et al., 2008), west Nile (Krishnan et al., 2008), Borna disease
(Clemente et al., 2010), human hepatitis C (Ng et al., 2007), and
vesicular stomatitis (VSV) (Pelkmans et al., 2005) viruses. Ideally,
these cell products might represent potential antiviral therapeutic
targets.
Here, the PI-induced inhibition of replication of both VSV and
inﬂuenza virus is described for the ﬁrst time. This was most likely a
consequence of a PI-dependent block of the viral envelope fusion at
the endosomes. Considering that PIs are well tolerated drugs in
vivo, and that many relevant human pathogens belong to the family
of RNA viruses infecting cells through an endocytic pathway, this
ﬁnding would open the way towards a broader therapeutic use of
PIs.
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Ritonavir decreases the infectivity of VSV-G pseudotyped HIV-1
HIV virions emerging from cells treated with PIs remain
immature viral particles as a consequence of the block of Gag
polyprotein cleavage. Hence, PIs do not affect the amounts of HIV
release from infected cells, but dramatically decrease their
infectivity. Surprisingly enough, however, the HIV-1 release from
cells infected with HIV-1 pseudotyped with the envelope protein
from VSV (VSV-G) has been found inhibited by PIs in single cycle
replication assays. In fact, when CEMGFP cells, i.e., a human T CD4+
lymphoblastoid cell line expressing GFP under the control of HIV-1
LTRs (Gervaix et al., 1997), were infected with 100 ng HIV-1 CAp24
equivalent/105 cells of (VSV-G) Δenv HIV-1, decreased percentages
of HIV-1 expressing cells were observed in ritonavir-treated cells as
compared to control conditions (Fig. 1A). The outcome did not
change by challenging the cells with doses up to 300 ng HIV-1
CAp24 equivalent/105 cells (not shown). Conversely, and as
expected, the PI-treatment had no apparent effects on single cycle
replication of non-pseudotyped HIV-1, as tested in PI-treated
cultures of CEMGFP cells infected with wt HIV-1 (Fig. 1B). In theseB
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Fig. 1. Ritonavir inhibits the expression of (VSV-G) HIV-1. (A) PI-induced inhibition of the e
ritonavir (RTV), the same volume of vehicle (DMSO), or left untreated, and then were infe
expression was evaluated in terms of GFP expression at the indicated days post infection. Th
experiments. Asterisks indicate p values b0.05. (B) Ritonavir does not affect the HIV-1 single
cells pre-incubated with 5 μM RTV, the same volume of DMSO, or left untreated, were infec
washed 16 h later, and part of them where treated with 1 μg/ml of T-20. The viral expression
post infection for T-20 treated cultures (left panel), and 6 days post infection for cells not tr
calculated from three independent experiments. (C) PM4 HIV-1 strain resists the PI treatme
equivalent/105 cells of PM4 HIV-1 and FACS analyzed 6 days later for the GFP expression. Th
experiments carried out with duplicated conditions. (D) PI-induced inhibition of the expr
combination with either 5 μM RTV or the same volume of DMSO, and then infected with
measured in terms of GFP expression was detected at the indicated days post-infection. The
experiments. Asterisks indicate p values b0.05.experiments, the presence of T-20 (i.e., a potent inhibitor of the
HIV-1 Env-mediated fusion) (Kilby et al., 1998) added 16 h after
challenge ensured that the wt HIV-1 replication was limited to a
single cycle. As anticipated, ritonavir blocked the spread of wt HIV-
1 in multiple-cycle replication assay (Fig. 1B).
To exclude that the observed effect was a consequence of the
inhibition of some yet unidentiﬁed function of the HIV-1 protease at
an early step of the virus life cycle, the assay was reproduced using a
VSV-G pseudotyped, PI-resistant HIV-1 strain (here referred to as
PM4). This viral mutant expresses a PI-resistant viral protease as a
consequence of the four amino acid substitutions in the protease gene,
i.e., M46I, L63P, V82T, and I84V (Condra et al., 1995). First, the real
resistance to PIs of PM4 HIV-1 was checked by evaluating the
percentages of CEMGFP infected cells 6 days after the infection in the
presence or not of ritonavir (Fig. 1C). Then, CEMGFP cells treated with
T-20 were infected with (VSV-G) PM4 HIV-1 in the presence or not of
ritonavir. This experimental setting was representative of a single-
cycle replication assay since T-20 disabled both HIV-1 Env-mediated
viral entry and possible cell re-infections. Similarly to what observed
with (VSV-G) Δenv HIV-1 strain, a signiﬁcant inhibitory effect of
ritonavir on the HIV-1 expression was detected in (VSV-G) PM4
challenged cells (Fig. 1D). This strongly suggests that the viralwt HIV-1
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cted with 100 ng HIV-1 CAp24 equivalent/105 cells of (VSV-G) Δenv HIV-1. The viral
e results are given as mean values of percentages+SD calculated from ﬁve independent
cycle replication, while blocking the viral spread within the infected cell culture. CEMGFP
ted with 500 ng HIV-1 CAp24 equivalent/105 cells of wt HIV-1. Infected cultures were
was measured in terms of percentages of GFP+ cells measured by FACS analysis 3 days
eated with T-20 (right panel). The results are given as mean values of percentages+SD
nt. CEMGFP cells treated or not with 10 μM RTV were infected with 500 ng HIV-1 CAp24
e results are given as mean values of percentages+SD calculated from two independent
ession of (VSV-G) PM4 HIV-1. CEMGFP cells were pre-incubated with T-20 alone or in
100 ng HIV-1 CAp24 equivalent/105 cells of (VSV-G) PM4 HIV-1. The viral expression
results are given as mean values of percentages+SD calculated from three independent
Fig. 2. Effects of different PIs on VSV replication. (A,B) PI effects on single cycle replication of VSV. HeLa cells were treated overnight with the indicated concentrations of different PIs
or equivalent volumes of DMSO, and then infected with 0.2 m.o.i. of VSV. After 1 h adsorption, cells were extensively washed and refed in the presence of PIs. Supernatants were
harvested 8 h later, clariﬁed, and the contents of infectious VSV were measured by the end-point dilution method. Ctrl: untreated infected cells. RTV: ritonavir; IND: indinavir; SAQ:
saquinavir; NEL: nelﬁnavir; AMPR: amprenavir; ATAZ: atazanavir. The results are given as mean values of percentages+SD calculated from six independent experiments. Single
asterisks indicate p values b0.05. Double asterisks indicate p values b0.01. (C) PI-induced inhibition of VSV yield in multiple-cycle replication assay. HeLa cells were treated with PIs
as indicated, and then challenged with 2-fold decreasing amounts of VSV starting to m.o.i. 2. The VSV-induced cytopathic effect was scored 24 h later. The results are given as fold-
reduction of the end-point dilution as compared with untreated infected cells, and are given as mean values of percentages+SD calculated from three independent experiments.
Single asterisks indicate p values b0.05. Double asterisks indicate p values b0.01. (D) Dose–response effect of PIs on HeLa cell duplication. Cells were treated for 8 h with different
concentrations of the indicated PIs, then labeled with CFSE, and afterwards incubated for additional 12 h. Finally, cells were harvested, and CFSE-related ﬂuorescence evaluated by
FACS analysis. In the shown experiment, the mean ﬂuorescence intensity (MFI) of control cells at the end of labeling was 151. The results are given as means of MFI from duplicate
conditions from a representative of two experiments. Asterisks denote over 20% of cell mortality. In the inset, both IC50 and CC50 for each PI are reported.
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Fig. 2 (continued).
40 M. Federico / Virology 417 (2011) 37–49protease activity was not involved in the PI-induced inhibition of
(VSV-G) HIV-1 expression.
Overall, these results can be a consequence of a still unrecognized
inhibitory effect of PIs on some step of the viral entry driven by VSV-G.
PIs strongly inhibit VSV replication
Next, the possibility that the PI inhibitory effect was operative also
against VSV was investigated. To this end, HeLa cells were pre-treated
overnight with different concentrations of six PIs, i.e., ritonavir,
indinavir, saquinavir, nelﬁnavir, amprenavir and atazanavir. Then, the
cells were challenged with 0.2 m.o.i. of VSV. After 1 h of adsorption in
a small volume, the viral inoculumwas removed, the cells extensively
washed, and incubated for additional 8 h in the presence of PIs.
Afterwards, the supernatants were harvested and titrated for the
amounts of infectious VSV. As depicted in Figs. 2A–B, a strong
reduction of VSV replication (more than 2 logs) was observed when
the cells were treated with 2.5 μM saquinavir and nelﬁnavir. The
inhibitory effect appeared more potent (up to about 4 logs) by
increasing the concentration of these PIs to 10 μM, and remained
signiﬁcant (i.e., more than 1 log) by increasing the m.o.i. up until 1
(not shown). No differences were observed when the PIs pre-
treatment was carried out for 2, 4, 6, or 8 h (not shown). As calculated
through a wide dose–response curve, the 50% inhibitory concentra-
tion (IC50) values of saquinavir and nelﬁnavir were 1.4 and 1.1 μM,
respectively. On the other hand, signiﬁcant inhibition of viral
replication were detected in ritonavir and indinavir treated cells
starting to the concentrations of 20–30 μM (Fig. 2B). The IC50 of
ritonavir and saquinavir were 16 and 14 μM, respectively.
The idea that PIs negatively affect the VSV replication was further
strengthened by performing a set of more stringent challenge
experiments. In detail, HeLa cells were pre-treated with optimal
concentrations of the most effective PIs, and then infected with 2-fold
decreasing amounts of VSV starting to m.o.i. 2. The cytopathic effect
was monitored 24 h post challenge. The outcome of this assay was
scored in terms of the viral dilutions no more able to induce
cytopathic effect. Notably, in these conditions an about 30-fold
reduction of VSV infectivity was observed in cells treated with
saquinavir or nelﬁnavir (Fig. 2C). Since the average replication time ofVSV is 6–8 h (Whelan et al., 2004), in this experimental setting VSV
was expected to complete at least three replication cycles in control
cells.
Then, it was controlled whether the antiviral effect was a
consequence of a general cytotoxicity of PIs. To this aim, cells were
treated with different PI concentrations for 8 h, then labeled with
carboxyﬂuorescein diacetate succinimidyl ester (CFSE), and thereafter
refed with complete medium in the presence of PIs. CFSE was
expected to be equally distributed upon cell division, then resulting in
a halving of the overall cell ﬂuorescence after cell duplication.
Cytotoxic effects were measured in terms of inhibition of the cell
duplication as detectable by the impairment of the halving of the
CFSE-associated cell ﬂuorescence. Fig. 2D reports the mean ﬂuores-
cence intensities (MFIs) measured in cell cultures treated with
different concentrations of the PIs active against VSV replication.
Block of cell duplication with cell mortality over 20% has been
detected using 100 μM ritonavir, saquinavir, and nelﬁnavir, while
indinavir showed a much lower cytotoxic effect. The 50% cytotoxic
concentration (CC50) values of PIs (Fig. 2D, insert) were calculated as
the doses inhibiting by 50% the ﬂuorescence halving, expectedly a
consequence of the block of the duplication in 50% of cells. The
therapeutic indexes (i.e., CC50 divided by IC50) appeared higher than
22 for both saquinavir and nelﬁnavir. This is suggestive of speciﬁc
antiviral effects for these PIs.
Taken together, these data reveal a previously unrecognized effect
of PIs against VSV. In addition, these results support the idea that the
PI-induced reduction of (VSV-G) HIV-1 expression is a consequence of
the inhibition on some step of the viral entry involving the VSV-G
envelope protein.
PIs inhibit the replication of H1N1 inﬂuenza A virus
To add relevance to our ﬁndings, the possibility that the inhibitory
effect of PIs applied also to alternative virus species infecting by pH-
dependent fusion was investigated. To this aim, the well characterized
inﬂuenza virus/MDCK cell system was considered. MDCK cells were
treated overnight with different PIs, and then challenged with m.o.i. 0.1
and 0.5 of the PR8 inﬂuenza virus. After challenge, the cells were
extensively washed, and reseeded in medium without serum in the
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Fig. 3. Effects of PIs on inﬂuenza virus replication. (A) PIs negatively affect the inﬂuenza virus replication. MDCK cells were treated overnight with the indicated concentrations of PIs
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41M. Federico / Virology 417 (2011) 37–49presence of both PIs and tosylamido-2-phenil ethyl chloromethyl ketone
(TPCK)-treated trypsin. Twenty-four h later (i.e., the expected time for
the completion of the replication cycle of inﬂuenza virus) (Sidorenko
and Reichl, 2004; Smith and Ribeiro, 2010), the supernatants were
harvested and titrated for the contents of infectious particles. A strong
inhibition of the replication of inﬂuenza virus (up to 4 logs at the lower
m.o.i.) has been detected with 10 μM saquinavir and 5 μM nelﬁnavir
(Fig. 3A). Ritonavir inhibited the viral replication less efﬁciently (Fig. 3A),
while indinavir, amprenavir and atazanavir appeared ineffective (not
shown). In the interpretation of these data, it should be emphasized that
the inhibitory effect of PIs cannot be a consequence of a PI-induced
impairment of the activation of the hemagglutinin envelope protein
(HA) of the inﬂuenza virus, which is a step required for productive
infection (Steinhauer, 1999). In fact, inﬂuenza virus preparations used
for challenges were exclusively recovered from the allantoic ﬂuid of
embryonated chicken eggs, where HA is cleaved by egg proteases.
Consistently, TPCK-trypsin did not inﬂuence the infectivity of the virus
preparations in single cycle replication assay (not shown).The cell cytotoxicity of PIs active against inﬂuenza virus was then
evaluated in MDCK cells similarly to what above described for HeLa
cells (Fig. 3B). Block of cell duplication in the presence of cell mortality
over 20% has been detected with 100 μM ritonavir and saquinavir, and
with 50 μM nelﬁnavir. The therapeutic indexes appeared higher than
15 for both saquinavir and nelﬁnavir. The assay gave similar results
when the cells were analyzed 24 h after CFSE labeling (not shown).
Taken together, these data suggest that PIs could target the
replication of diverse enveloped viruses infecting by a pH-dependent
endocytic pathway.
PIs do not inhibit the replication of viruses infecting by a
pH-independent mechanism
Next, it was investigated whether the PIs most effective against
VSV and inﬂuenza virus replication counteract also the replication of
viruses infecting by a pH-independent mechanism. As a proof of
principle, the PIs were assayed against the replication of Newcastle
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saquinavir or nelﬁnavir, and challenged with 0.2 m.o.i. VSV or 0.5 m.o.i. inﬂuenza virus. Afte
10× volumes of PBS, and infected cultures were refed with appropriate medium in the absen
virus infection) later, and titrated for the respective virus contents by the end-point dilution
independent experiments for both VSV (left panel) and inﬂuenza virus (right panel) challeng
challenge. VSV (0.2 m.o.i.) and inﬂuenza virus (0.5 m.o.i.) were adsorbed on HeLa and MDC
washed 5 timeswith 10× volumes of PBS, and then refed in appropriate medium. At this time
concentration of 5 μM. After 8 h (for VSV infection) and 24 h (for inﬂuenza virus infection), su
results are given as percentages of inhibition as compared with PI-treated infected cell c
independent experiments with triplicate conditions are reported.
42 M. Federico / Virology 417 (2011) 37–49Disease virus (NDV), i.e., a Paramixovirus infecting upon fusion at the
cell surface. MDCK cells were pre-treated with 2.5 to 10 μMsaquinavir
or nelﬁnavir, and then infected with 2-fold decreasing amounts of
NDV starting tom.o.i. 1. The cytopathic effect wasmonitored 48 h post
challenge. No signiﬁcant reductions in the NDV infectivity have been
noticed in PI-treated as compared to control cell cultures (Fig. 4).
These results indicate that PIs do not affect the replication of viruses
entering by a pH-independent way.
The inhibitory effect is operative when PIs are co-administered with the
infecting virus
To identify the virus replication step targeted by PIs, the effects of PIs
added before and/or after viral challenge were evaluated. The assays
were carried out using both HeLa/VSV and MDCK/inﬂuenza virus
systems. In a ﬁrst set of experiments, the PI treatmentwas discontinued
just before the virus challenge. Then, the cells were infected with VSV
or inﬂuenza virus at m.o.i. of 0.2 and 0.5, respectively. After 1 h of
adsorption, the cells were extensively washed and refed in the
appropriatemedium. In these conditions, no inhibitionof the replication
of both VSV and inﬂuenza virus was detectable (Fig. 5A).
Alternatively, PIs were added soon after the virus adsorption or at
different times after the challenge within a timeframe of 8 h (for VSV
infection) and24 h (in the caseof challengewith inﬂuenzavirus), i.e. the
respective replication times. The supernatants were harvested 8 h (for
VSV) and 24 h (for inﬂuenza virus) post-infection, and titrated for the0
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method. The results are given as mean values of percentages+SD calculated from three
es. (B) Effects on VSV and inﬂuenza virus replication of PIs added at different times after
K cells, respectively. After 1 h at 37 °C, the viral inocula were removed, the cells were
, or at the indicated post-infection times, saquinavir or nelﬁnavir were added at the ﬁnal
pernatants were harvested, clariﬁed, and then titrated for infectious virus contents. The
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44 M. Federico / Virology 417 (2011) 37–49amounts of infectious virus particles. It appeared that PIs inhibited the
virus replication also when added early after challenge (Fig. 5B). The
inhibitory effect dropped shortly in the case of VSV infection, and more
gradually when cells were infectedwith inﬂuenza virus. Saquinavir and
nelﬁnavir have shown similar inhibitory efﬁciencies (not shown).
These results indicate that the presence of PIs at early times after
virus challenge is mandatory for the inhibitory effect, consistentlyA
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further supported the idea that PIs would inﬂuence some common
early replication step, e.g., virus attachment, endocytosis, and/or
endosomal fusion.
To dissect among these different possibilities, the intracellular fate
of challenging virus was followed using GFP-labeled HIV-1-based
VLPs (Muratori et al., 2006) pseudotyped with either wt or fusion-
defective VSV-G (Fig. 6A). The ﬂuorescence of these VLPs relies on the
high incorporation levels of the product of fusion between GFP and a
HIV-1 Nef mutant acquiring a palmitoylation site at its N-terminus as
the consequence of the G to C substitution at the amino acid 3. First,
the possible effects of PIs on the virus attachment on target cells were
investigated. To this end, 105 HeLa cells treated or not with PIs were
challenged with 500 ng of (wt VSV-G) NefG3C-GFP VLPs for 1 h at 4 °C.
Afterwards, the cells were extensively washed and FACS analyzed. To
control that the cell-associated ﬂuorescence was not a consequence of
endocytosed VLPs, a part of the cell samples was treated with trypsin.
It appeared that the treatment with PIs did not signiﬁcantly affect the
cell binding of ﬂuorescent VLPs (Fig. 6B). This strongly suggests that
PIs do not interfere with the binding of viral particles on the cell
membrane.
Next, the inﬂuence of PIs on virus endocytosis was investigated. To
this aim, GFP-ﬂuorescent VLPs incorporating a VSV-G mutant (here
referred to as fd VSV-G) unable to support the pH-dependent fusion
were used. The impaired fusion activity was a consequence of the A to
K amino acid substitution at the position 133 (Fredericksen andWhitt,
1995). The use of this envelope protein mutant was associated with
the trypsin treatment just before the FACS analysis to ensure that the
cell-associated ﬂuorescent signal exclusively referred to the intracel-
lular accumulation of VLPs. HeLa cells treated or not with PIs were
challenged with 500 ng HIV-1 CAp24 equivalents of (fd VSV-G)
NefG3C-GFP VLPs/105 cells, and incubated for 3 h at 37 °C in the
presence or not of PIs. Then, the cells were treated with trypsin, and
the cell-associated GFP ﬂuorescence was evaluated by FACS analysis.
As control, VLP-challenged cells were incubated at 4 °C before the
trypsin treatment. Again, no apparent differences in the cell-
associated ﬂuorescence were detected between control and PI-treated
cells (Fig. 6C), suggesting that PIs have no inﬂuence on the efﬁciency
of the endocytosis of viral particles.
This conclusion was enforced by the results obtained through an
alternative experimental approach where control or PI-treated HeLa
cells were infected with 0.2 pfu/cell of VSV. Thirty and 60 min later,
the cells were extensively washed, treated with trypsin to leave out
non-adsorbed viral particles, lysed, and analyzed by western blot forthe presence of VSV-G. No signiﬁcant reduction of the VSV-G speciﬁc
signals was detectable at both time points in PI-treated cells as
compared to control conditions (Fig. 6D). Considering that the neo-
synthesis of VSV-G starts at least 90 min post-infection (Rothman and
Lodish, 1977), these results, consistently with the data obtained with
ﬂuorescent VLPs, suggest that PIs do not affect the endocytosis of viral
particles.
The results from these experiments indicate that the inhibitory
effect of PIs is not the consequence of impaired attachment and
endocytosis of viral particles.
PIs act at the level of intracellular viral fusion
Next, the possibility that the inhibitory effect of PIs was a
consequence of a defect in the endosome to cytoplasm virus delivery
was investigated. To this end, the differences in the cell-associated
ﬂuorescence levels in cells internalizing wt or fd VSV-G pseudotyped
NefG3C-GFP VLPs were exploited. In fact, using the same experimental
conditions described for the endocytosis assay, it was reproducibly
observed that, early afterVLP challenge, themeanﬂuorescence intensity
(MFI) of cells challenged with (wt VSV-G) VLPs was near 2-fold higher
than that of cells treatedwith (fd VSV-G) VLPs.More signiﬁcantly, in the
latter condition both percentages of ﬂuorescent cells and MFI heavily
dropped 16 h after challenge. On the contrary, both FACS parameters
appeared only slightly reduced in cells challengedwith (wtVSV-G)VLPs
(Fig. 7A). These differences can be explained by the fact that, due to the
inability of fd VSV-G to induce fusion and delivery of the VLP
contents into cytoplasm, the NefG3C-GFP molecules incorporated in
(fd VSV-G) VLPs were addressed to rapid degradation into the
endosomal/lysosomal compartment. Conversely, the efﬁcient fusion
between viral envelope and endosomemembranes induced bywt VSV-
G allowed the release of NefG3C-GFP molecules into cytoplasm, where
they are expected to be degraded with a kinetic much slower than that
operating in endosomes/lysosomes.
Next, PI-treatedoruntreatedHeLa cellswere challengedwith500 ng
HIV-1 CAp24 equivalent of either (wt VSV-G) or (fd VSV-G) NefG3C-GFP
VLPs/105 cells, and 3 and 16 h later, the cells were treated with trypsin.
FACS analysis of the cell-associatedGFPﬂuorescence revealed that thePI
treatment did not affect the ﬂuorescence levels in cells challenged with
(fd VSV-G) NefG3C-GFP VLPs at both time points. On the contrary, after
3 h it was observed a relevant reduction in the MFI within PI-treated
cells challenged with (wt VSV-G) NefG3C-GFP VLPs as compared with
untreated cells. More strikingly, a strong decrease of both MFI and
percentage of ﬂuorescent cells was detectable in PI-treated cells at 16 h
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saquinavir and nelﬁnavir produced the strongest inhibitory effect (data
not shown).
Next, dose–response endocytosis assays using different concen-
trations of nelﬁnavir were carried out by analyzing the cell-associated
ﬂuorescence 16 h after the challenge. The results showed that, within
the cells challenged with (wt VSV-G) NefG3C-GFP VLPs, the PI
treatment reduced both MFI and percentages of ﬂuorescent cells in
a dose-dependent manner. At the highest PI concentrations, both
parameters reached levels similar to those detectable in cells
challenged with (fd-VSV-G) NefG3C-GFP VLPs (Fig. 7C). Hence, it
seemed that the PI treatment diverted the fate of endocytosed (wt
VSV-G) towards that of (fd VSV-G) VLPs. This strongly suggests that
PIs negatively affect the fusion of viral envelope with the endosomal
membranes.
Together, these results support the idea that the inhibitory effect of
PIs acts at the level of the delivery of the viral particles from
endosomes to cytoplasm of infected cells.
PIs do not affect intracellular pH
A possible explanation for the apparent block of viral envelope
fusion could be that PIs may increase the pH in endosomes in a way to
inhibit the low pH-dependent conformational changes needed for
both VSV-G and inﬂuenza HA to switch the fusion process. To testM
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Fig. 8. The PI treatment does not affect intracellular pH. Cells were treated overnight with th
Lysosensor DND-189. After 30 min of incubation, cells were harvested, and the cell associa
mean ﬂuorescence intensity (MFI) of control conditions, i.e., cell cultures with or without
independent experiments with duplicate conditions.whether PIs affect intracellular pH, both HeLa and MDCK cells were
labeled with LysoSensor Green DND-189. This reagent becomes
ﬂuorescent only in acidic intracellular compartments, meanwhile
exhibiting decreased ﬂuorescence intensity upon pH increase. Thus, it
represents a useful reagent for detecting possible pH variations in
endosomes. Cells were treated overnight with the PI doses most
effective against VSV and/or inﬂuenza virus replication, then labeled
with LysoSensor Green DND-189 for 30 min in the presence of PIs, and
ﬁnally analyzed by FACS. As control, cells treated with baﬁlomycin A1,
i.e., a powerful inhibitor of the vacuolar ATPase proton pump, were
also tested. As depicted in Fig. 8, no signiﬁcant variations in the cell-
associated ﬂuorescence have been detected in PI-treated cells as
compared with control conditions, indicating that PIs do not affect the
intracellular pH. These results strongly suggest that the PI-induced
block of virus delivery in cytoplasm would not be a consequence of
the increase of endosomal pH.
Discussion
Viruses hijack cell functions to replicate in host cells. Hence, the
selective targeting of cell products supporting virus replication could
represent a successful antiviral strategy. The results from the here
described investigations indicate that drugs designed to counteract the
activity of the HIV protease show a strong inhibitory effect against
unrelated virus species likely by targeting yet unidentiﬁed proteaseAQ NEL
5 10 2.5 5 10
a cells
Bafilomycin A-1
0.05 0.1 0.2
NEL
2.5 5 10
K cells
Bafilomycin A-1
0.05 0.1 0.2
e indicated concentrations of PIs or, as control, of baﬁlomycin A1, and then labeled with
ted ﬂuorescence measured by FACS analysis. The results are reported as percent of the
appropriate dilutions of DMSO, and were calculated as the mean values+SD from two
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reached about 4 logs in the reduction of virus yields, with therapeutic
indexes higher than 15. The PI-induced effect against VSV appeared
comparable in magnitude to that observed in cell treated with type-1
interferons (Masters and Samuel, 1983). On the other hand, the potency
of PIs against the inﬂuenza virus replication appeared comparable to
that of most potent inhibitors. Among these, T-705 (Furuta et al., 2002)
reduced the viral yield of themost susceptible inﬂuenza strain tested of
at best 2.7 logs at the concentration of 5 μM upon MDCK cell challenge
with 0.01 m.o.i. (Sleeman et al., 2010). DAS181, i.e. a sialidase fusion
protein, blocked the inﬂuenza virus replication at sub-micromolar
concentrations, however when MDCK cells were challenged with
0.001–0.005 m.o.i. (Triana-Baltzer et al., 2009). Conversely, micromolar
concentrations of PIs induced more than 3 logs of reduction of the
inﬂuenza virus yield from MDCK cells challenged with 0.5 m.o.i.
In the challenge experiments where PIs were added soon after the
adsorption of VSV or inﬂuenza virus inocula, the antiviral effect
appeared slightly reduced as comparedwith control conditions where
PIs were maintained throughout. Considering also the results
obtained in the endocytosis assays, it is conceivable that this subtle
difference could be a consequence of the accession to cytoplasm of a
small amount of viral particles during the adsorption time and before
the PI treatment.
The possibility that PIs affect some virion structural component in
a way to hinder the process of fusion in endosomes appeared unlikely.
In fact, the treatment of 10-fold concentrated VSV or inﬂuenza virus
preparations with up to 500 μM PIs for 30 min before challenge did
not produce signiﬁcant decrease of the viral yields (not shown).
However, we cannot formally exclude that PIs inhibit some yet
unidentiﬁed protease activity associated with VSV-G or inﬂuenza
virions. In this regard, it has been proposed that PIs could negatively
affect the chymotrypsin-like protease activity of the PA subunit of the
RNA-directed RNA polymerase of inﬂuenza virus (Savarino, 2005).
Furthermore, it was reported that nelﬁnavir reduces the replication of
SARS coronavirus (Yamamoto et al., 2004) likely as a consequence of
the inhibition of the 3C-like viral protease (for a review, see 35).
The results from here reported experiments indicate that PIs act on
early events of viral replication, but not on virus attachment and
endocytosis. This latter ﬁnding was consistent with previously
reported results indicating that PIs do not affect the endocytosis of
HIV-1 particles in dendritic cells (Muratori et al., 2009). Rather, it
appeared that PIs interfere with the delivery of viral particles from
endosomes to cytoplasm. This did not seem to depend on a PI-induced
increase of the endosomal pH possibly inhibiting the low pH-
dependent conformational changes of viral envelope proteins re-
quired for viral fusion.
The concept that the activity of cell proteases is part of the
mechanisms underlying the replication of many virus species is
widely accepted. For example, the cleavage of HA generated by cell
proteases is required for the activation of the viral envelope protein
preceding the viral fusion of inﬂuenza virus (Klenk et al., 1975;
Lazarowitz and Choppin, 1975). Similarly, the activation of envelope
proteins of Ebola (Schornberg et al., 2006), Nipah (Pager and Dutch,
2005), and Corona viruses (Bosch et al., 2008) is regulated by
cathepsins, i.e., a family of cell aspartyl-proteases. The identiﬁcation of
host factors, in particular aspartyl-proteases, involved in the here
described PI-induced inhibition of viral entry deserves further
investigations.
The results from functional genetic screens have demonstrated
that alternative cell proteases act as co-factors in the replication of
different viruses (Brass et al., 2008; Clemente et al., 2010; Hao et al.,
2008; Krishnan et al., 2008; Ng et al., 2007; Nguyen et al., 2006;
Pelkmans et al., 2005). Concerning VSV, the comparison of these data
with those regarding the cell proteases known to be sensitive to PIs
identiﬁes both proteasome subunits as possible relevant PI targets
(Clemente et al., 2010). This appears consistent with the recentlyreported evidence that MG132 (i.e., a proteasome inhibitor) inhibits
VSV replication (Neznanov et al., 2008). Alternative functional genetic
screens revealed that also MMP-21 could be part of the mechanism of
VSV replication (Clemente et al., 2010). Considering that the activity
of MMP-21, like other MMPs, might be affected by PIs, it would be of
interest investigating the role of this MMP in the here described
antiviral effect of PIs.
The here reported ﬁndings would open the way towards pre-
clinical assays designed to test the potency of PIs against in vivo
infections sustained by Orthomyxo- and Rabies viruses. It will be also
of interest extending the investigations on additional pathogenic
enveloped viruses infecting by endocytosis.
Materials and methods
Virus preparations
VSV-G pseudotyped HIV-1 preparations were obtained from
supernatants of 293T cells 48 h after co-transfection with a CMV
immediate-early promoted VSV-G-expressing vector and vectors
expressing NL4-3 HIV-1, its Δenv derivative, or PM4 HIV-1 (molar
ratio 1:5) performed by the Lipofectamine 2000-based method
(Invitrogen). Supernatants were clariﬁed and concentrated by
ultracentrifugation as described (Federico et al., 2001). Virus
preparations were titrated by measuring HIV-1 CAp24 contents by
quantitative enzyme-linked immunosorbent assay (ELISA; Innoge-
netic). Both preparations and assays of VSV (Indiana strain) have been
performed basically as described (Gresser et al., 1968). Brieﬂy, high
titer stocks of VSV have been prepared upon infection of HeLa cells
with at low multiplicity of infection (m.o.i.), i.e. b0.01 plaque forming
unit (PFU)/cell. Supernatants were harvested 24 h later, clariﬁed,
stocked, and frozen. VSV titrations of high titer stocks have been
carried out by plaque method. The A/Puerto Rico (PR)/8/34 H1N1
human inﬂuenza virus was grown in 11-day-old embryonated
chicken eggs. The allantoic ﬂuid was clariﬁed by centrifugation at
5000×g for 15 min at 4 °C. The virus was pelleted by centrifugation at
65,000×g for 1 h at 4 °C and resuspended in 1 ml of phosphate-
buffered saline. Portions of the solution were stored as aliquots at
−20 °C. Inﬂuenza preparations were titrated by standard plaque
assay on MDCK cells. Virus titers for these stocks ranged from 1 to
8×107 PFU/ml. Preparations of the Hertz strain of NDV were
recovered after 48 h of incubation in 9–11-day-old embryonated
chicken eggs inoculated in the allantoic cavity. After harvesting, the
allantoic ﬂuid was clariﬁed by centrifugation at 10,000×g, and titrated
as infectious units/ml through the end-dilution method by assessing
the cytopathic effect onMDCK cells 48 h post infection. The titer of the
viral stock used was 2.1×107 infectious units/ml.
Cell cultures, infections, and titrations
CEMGFP cells were grown in Roswell Park Memorial Institute
(RPMI) medium supplemented with 10% heat-inactivated fetal calf
serum (FCS). HeLa, MDCK, 293T and 293/GPR inducible HIV-1
packaging cells (Sparacio et al., 2001) were grown in Dulbecco's
modiﬁed Eagle's medium plus 10% FCS.
Infections of CEMGFP cells with HIV-1 or pseudotyped derivatives
were carried out by spinoculation at 400×g for 30 min at room
temperature (r.t.) using 200 ng and 50 ng CAp24 equivalent of HIV-1
and (VSV-G) HIV-1/105 cells, respectively. Then, virus adsorption was
prolonged for additional 2 h at 37 °C and, ﬁnally, cells were washed
and refed with the complete medium. HeLa cells were infected with
VSV by adsorbing the viral inoculum for 1 h at 37 °C in a small volume
(e.g., 0.1 ml of serum free medium for 2×105 cells in 12 well plates).
Thereafter, the cells were extensively washed, and refed with
appropriate complete medium.
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challenges were carried out as for VSV infection, except that after
virus adsorption, cells were refed with medium without serum in the
presence of 1 μg/ml of TPCK-treated trypsin (Worthington Biochem-
ical Corporation).
HeLa andMDCK cells served to titrate infectious VSV and inﬂuenza
virus in supernatants harvested after challenge experiments. The
titrations were carried out by the end-dilution method with triplicate
conditions by challenging the cells with 3-fold scaled supernatant
dilutions (in the presence of 1 μg/ml TPCK-trypsin for inﬂuenza virus
titrations), and by evaluating the cytopathic effect after 36 h (for VSV)
and 72 h (for inﬂuenza virus). Concentrated virus preparations
previously titrated by the plaque assay were used as standards.
For NDV infections, MDCK cells were challenged with 2-fold
decreasing viral dilutions starting to m.o.i. 1, and the cythopatic effect
was assessed 48 h later.
T-20, ritonavir, indinavir, saquinavir, nelﬁnavir, amprenavir and
atazanavir were obtained from the NIH AIDS Research and Reference
Reagent Program.
CFSE-based cell duplication assay
Both control and PI-treated cells were labeled with 1 μM CFSE
(Molecular Probes, Invitrogen) following the manufacturer's recom-
mendations. A cell sample was immediately processed to determine
the ﬂuorescence levels at the zero time. Thereafter, the remainder
cell cultures were refed with complete medium and, at the time of
completion of one cell duplication (on the average, 12 h for both HeLa
and MDCK cells at their logarithmic phase), were harvested, and the
ﬂuorescence measured by FACS analysis. Dead cells were identiﬁed
upon labeling with 5 μg/ml of propidium iodide (Sigma-Aldrich).
Preparation of ﬂuorescent VLPs, challenge, and detection assays
Fluorescent VLPs were obtained as previously described (Muratori
et al., 2009). Brieﬂy, 293/GPR HIV-1 packaging cells were co-
transfected with vectors expressing the green-ﬂuorescent protein
(GFP) fused at its N-terminus with a G3C HIV-1 Nef mutant,
together with a vector expressing wt or fusion-defective (fd) VSV-G
(Fredericksen and Whitt, 1995). Supernatants were harvested 2 days
later, concentrated by ultra-centrifugation on 20% sucrose cushion,
and titrated for the HIV-1 CAp24 contents.
For HeLa cell challenge, 500 ng CAp24 equivalent of ﬂuorescent
(VSV-G) HIV-1 VLPs/105 cells were adsorbed for 1 h at 4 or 37 °C in a
volume of 0.1 ml in 48 well plates. Thereafter, 0.1 ml of complete
medium was added and, ﬁnally, the cells were extensively washed
and analyzed by FACS. In the endocytosis assays, the FACS analysis
was carried out after incubation with trypsin for 15 min at 37 °C.
Western blot analysis
Both cells and puriﬁed VLP preparations were lysed in PBS, 1%
Triton X-100 in the presence of anti-proteolytic agents. For the
preparation of cytoplasmic extracts, whole cell lysates were centri-
fuged at 6000×g for 10 min at 4 °C, and the supernatants frozen at
−80 °C. Aliquots of 200 ng HIV-1 CAp24 equivalent of VLPs and of
30 μg of total cell proteins were separated in 10% SDS-PAGE, and then
transferred by electroblotting on nitrocellulose membranes (Sartorius
AG) for 60 min at 100 V with a Bio-Rad transblot. Nitrocellulose
membranes were blocked in 3% bovine serum albumin (BSA) fraction
V (Sigma) in TTBS/EDTA (10 mM Tris–HCl, pH 7.4; 100 mM NaCl;
1 mM EDTA; 0.1% Tween-20) for 30 min at room temperature, then
incubated for 1 h at r.t. with speciﬁc antibodies diluted in 1% BSA/
TTBS-EDTA. The following Abs served for the revelation of both VLP-
and cell-associated products: ARP 444 sheep anti-Nef antiserum from
Mark Harris, University of Leeds, Leeds, UK; rabbit polyclonal anti-VSV-G Abs from Immunology Consultant Laboratories; monoclonal
anti human β-actin from Amersham Pharmacia Biotech. Immune
complexes were detected through horseradish peroxidase-conjugat-
ed goat anti-sheep, anti-rabbit (both from Calbiochem) and anti-
mouse Abs (NEN), followed by enhanced chemioluminescence
reaction (Euroclone).
Detection of intracellular pH variations
The Lysosensor probe DND-189 (Molecular Probes, Invitrogen)
served to detect possible changes in the endosomal pH upon PI
treatment. This is an acidotropic probe accumulating in acidic
organelles which exhibits decreasing ﬂuorescence upon pH in-
crease. Cells pre-treated with PIs or, as control, with baﬁlomycin A1
(Sigma-Aldrich) were labeled with 1 μM of Lysosensor DND-189 in
complete medium for 30 min in the presence of the drugs.
Afterwards, cells were extensively washed, ﬁxed, and ﬂuorescence
evaluated by FACS analysis.
Statistical analysis
When appropriate, data are presented as mean+standard
deviation values (SD). In some instances, statistical analysis was
performed according to paired Student's t-Test, and conﬁrmed using
the non-parametric Wilcoxon rank sum test. P-values b0.05 were
considered signiﬁcant.
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